Animal studies and preliminary human data suggest sildenafil could be safe for treating Leigh syndrome, though effectiveness remains unproven.
Researchers are investigating sildenafil, the active compound in Viagra, as a potential treatment for Leigh syndrome, a fatal genetic disease. Animal studies and early human data indicate the drug appears safe for patients with this rare condition, though its therapeutic effectiveness has not yet been established.
Leigh syndrome is a severe neurometabolic disorder that typically affects infants and young children, causing progressive deterioration of mental and movement abilities. The condition is caused by defects in cellular energy production and currently has no approved treatments, making any potential therapeutic breakthrough significant for affected families.
The research builds on sildenafil's established safety profile from its widespread use in treating erectile dysfunction and pulmonary arterial hypertension. While preliminary safety data is encouraging, researchers emphasize that proving clinical efficacy will require more extensive trials with larger patient populations.
If successful, this repurposing approach could accelerate treatment development for Leigh syndrome patients who currently face limited options. The research represents part of a broader trend in medicine toward finding new applications for existing drugs, potentially reducing development costs and timelines for rare disease treatments.
The findings highlight ongoing challenges in developing therapies for ultra-rare genetic conditions that affect small patient populations.